Aim Immunotech Inc

Proposal 1 requests stockholder authorization to issue shares exceeding 19.99% of outstanding common stock that would be issuable upon exercise of the Class H common stock purchase warrants issued under the May 7, 2026 Inducement Letter. Management completed the inducement transaction, receiving approximately $3.5 million in initial gross proceeds, and the Class H Warrants could generate an additional up to approximately $8.9 million if exercised for cash in full; NYSE American rules require stockholder approval because the potential issuance could trigger the 20% issuance threshold or a change of control. The Company also agreed to registration obligations and engaged a placement agent whose fees and warrants were described in the filing. Board approval is not the transaction approval (the deal has closed) but a required post-closing stockholder approval to comply with exchange rules and to permit holders to exercise for cash. The board recommends FOR because approval would preserve the company’s ability to access near-term equity capital, provide flexibility to pursue growth objectives, and avoid repeated special meetings required under the inducement agreement. Risks include dilution to current shareholders if the warrants are exercised and potential downward pressure on the stock price, as well as uncertainty whether warrant holders will exercise. The Company warns that failing to approve could materially impair its ability to raise capital and could jeopardize operations given limited cash runway. In evaluating the merits, analysts should weigh the immediate liquidity benefits and avoidance of repeated proxy solicitations against dilution, change-in-control risk if a holder becomes a large shareholder, and the possibility that shares may be issued on a cashless basis if registration is not effective, which alters proceeds. Overall, the board frames the proposal as necessary compliance and a path to potential financing; shareholders must consider dilution, timing uncertainty of exercises, and the company's near-term financing needs.

Proposal 2 asks stockholders to permit issuance in excess of 19.99% of outstanding common stock upon exercise of Class I warrants issued in the May 20, 2026 registered direct offering and paired private placement. The May 2026 transactions raised roughly $2.4 million in gross proceeds and included 15,038,702 Class I Warrants exercisable at $0.325 per share, which if exercised for cash could generate approximately $4.9 million additional proceeds; the company has committed to filing a registration statement to enable resale of underlying shares. NYSE American’s 20% rule and change-of-control provisions require stockholder approval for such potentially dilutive issuances. Management seeks approval to preserve access to capital and to permit the purchasers to exercise their warrants for cash, improving liquidity and funding runway. The board recommends FOR, emphasizing the potential to raise additional capital, while disclosing dilution risk and the uncertainty of actual exercises. Opposing considerations include potential dilution, downward share-pressure, and the fact that warrants may be exercised on a cashless basis if registration is not effective, reducing expected proceeds. For analysts, the key trade-off is near-term capital availability versus long-term dilution and governance implications if warrant holders accumulate a significant stake. Given the company’s stated insufficient cash runway absent new capital, the board frames approval as critical to avoid operational disruptions, but shareholders should assess valuation, alternative financing options, and potential long-term impact on share count and control.

Proposal 3 seeks stockholder authorization for the potential issuance of more than 19.99% of outstanding common stock upon exercise of Class J warrants issued in the company’s June 9, 2026 financings. The June 2026 transactions generated approximately $2.65 million in gross proceeds and included Class J Warrants to purchase up to 10,216,476 shares at $0.5189 per share, which could yield an incremental approximately $5.3 million if exercised for cash in full. NYSE American rules require stockholder approval when proposed issuances could reach the 20% threshold or effect a change of control; management is seeking approval to comply and to preserve the capacity to raise incremental capital. The board recommends FOR on grounds that approval would increase financial flexibility and support ongoing operations and growth initiatives, while acknowledging dilution and volatility risks. Key risks include dilution to legacy shareholders, potential concentration of ownership if a single investor exercises and holds a large block, and the uncertainty of whether and when exercises will occur; registration obligations were described to facilitate cash exercises. Analysts should weigh the immediate benefit of potential funding against the erosion of ownership and possible share-price pressure; the company’s disclosures emphasize limited cash runway and material adverse consequences if additional capital is not obtained. In sum, the board positions approval as a necessary compliance step to enable financing certainty, but shareholders must evaluate the balance between critical capital needs and long-term dilution and governance effects.

Proposal 4 requests stockholder approval to permit issuance of shares in excess of 19.99% upon conversion or other satisfaction of the company’s February 16, 2024 promissory note issued to Streeterville Capital, LLC. The note originally had a principal amount and features including issuance discounts, fees, 10% annual interest compounded daily, monthly partial redemption rights for the noteholder, and amended maturity (now June 30, 2027); the noteholder has previously accepted settlement in common stock for amounts coming due. Management seeks approval to comply with NYSE American rules so that the company may continue to issue shares to satisfy obligations under the note (and avoid large cash payments) if permitted by the noteholder. The board recommends FOR, arguing that authorizing share issuance preserves the company’s liquidity by allowing equity settlement instead of immediate cash payments and reduces near-term cash burn. Downsides include additional dilution, potential share price pressure, and uncertainty about the conversion rate (the company describes a methodology tied to trading prices that will affect the number of shares issued). The filing warns of material adverse consequences if additional capital is not raised and stresses that failure to approve could impede fundraising and operations. For analysis, the central trade-off is avoiding cash outflows and preserving operations versus diluting existing holders and possibly increasing the noteholder’s stake; governance implications depend on the resulting share concentration. Investors should consider the contingent nature of the issuance, conversion mechanics, and how much of the note is likely to be satisfied by equity versus cash.

Proposal 5 seeks stockholder permission to issue shares exceeding 19.99% of outstanding common stock upon conversion or other satisfaction of the November 18, 2025 promissory note. That note was issued in a private placement with similar economic features to the February 2024 note (issuance discount, interest, redemption mechanics, and mandatory prepayment tied to future financings) and as of the record date approximately $2.886 million remains outstanding; the company may seek to satisfy amounts due by issuing common stock if the noteholder permits. Management frames approval as necessary to comply with NYSE American rules and to preserve flexibility to conserve cash by issuing equity in lieu of cash payments, potentially easing near-term liquidity pressures. The board recommends FOR, citing the need to maintain operations and raise capital without depleting cash reserves. Key investor considerations include significant dilution if issuance occurs, possible changes to ownership concentration, and the mechanics used to calculate share issuance (based on trading price over prior days), which could produce widely varying share counts. The company warns of operational risk without new capital, which supports management’s urgency, but shareholders must weigh dilution, timing uncertainty, and governance implications; analysts should scrutinize whether alternative financing or restructuring could be less dilutive.

Proposal 6 requests stockholder approval of a series of alternate Certificate of Incorporation amendments that would allow the Board, at its sole discretion and within one year, to implement a reverse stock split of up to 1-for-25. Management’s stated rationale includes improving marketability and liquidity by increasing the per-share trading price, avoiding automatic delisting from NYSE American if the price drops to $0.10, meeting brokerage and institutional investor price thresholds, and reducing volatility and transaction costs associated with low-priced stocks. The Board argues that granting discretion on the exact ratio provides flexibility to choose a ratio reflective of market conditions at the time of any implementation. The filing also discloses risks: a reverse split may not sustain a higher price, could reduce liquidity and increase odd-lot holdings, and results in an effective increase in the number of authorized but unissued shares (potential anti-takeover effects). The board recommends FOR noting that the company previously effected a 1-for-100 reverse split in June 2025 and that approval would be precautionary, not an immediate commitment to act. For analysts, the key considerations are the company’s fragile share price history, the potential benefit of avoiding delisting versus the possibility of signaling desperation or worsening liquidity, and the anti-takeover implications of increased available authorized shares. Shareholders should evaluate whether empowering the Board with broad discretion appropriately balances the need to preserve listing status and marketability against dilution, potential governance impacts, and the historical ineffectiveness of prior reverse splits in sustaining share price.

Proposal 7 seeks stockholder approval to allow the company to adjourn the Special Meeting to solicit additional proxies if there are insufficient votes to approve any of the other proposals at the time of the meeting. Management presents this as a procedural safeguard to ensure adequate time and opportunity to obtain required approvals, and to allow previously submitted proxies to be revoked or changed prior to any adjourned vote. The board recommends FOR so the company can comply with contractual obligations (e.g., inducement agreements) that may require repeated meetings and to avoid failed votes due to insufficient participation. Because this proposal is routine in nature, brokers may have discretionary authority to vote on it, which can be critical to allow further solicitation without losing quorum or other procedural standing. Risks to shareholders are minimal substantively, though approval could permit the company to continue soliciting and incur additional solicitation costs; however the company argues such costs are justified to avoid operational disruption if critical financing-related proposals fail. Analysts should treat this as a housekeeping measure that increases the likelihood that the financing- and governance-related proposals receive final votes, and should consider how repeated adjournments could signal closely contested support for the company’s capital strategy.